Adverum Biotechnologies Dirección
Dirección controles de criterios 3/4
El CEO de Adverum Biotechnologies es Laurent Fischer , nombrado en Jun 2020, tiene una permanencia de 4.42 años. compensación anual total es $1.55M, compuesta por 43.4% salario y 56.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.34% de las acciones de la empresa, por valor de $433.75K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 4.5 años, respectivamente.
Información clave
Laurent Fischer
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 43.4% |
| Permanencia del CEO | 4.4yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13
Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$94m |
| Jun 30 2024 | n/a | n/a | -US$100m |
| Mar 31 2024 | n/a | n/a | -US$113m |
| Dec 31 2023 | US$2m | US$672k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$126m |
| Jun 30 2023 | n/a | n/a | -US$133m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$3m | US$646k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$156m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$155m |
| Dec 31 2021 | US$9m | US$621k | -US$146m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$138m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | US$22m | US$327k | -US$118m |
Compensación vs. Mercado: La compensación total de Laurent($USD1.55M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Laurent ha sido consistente con los resultados de la empresa en el último año.
CEO
Laurent Fischer (60 yo)
4.4yrs
Permanencia
US$1,546,477
Compensación
Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.4yrs | US$1.55m | 0.34% $ 433.8k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.9yrs | US$2.30m | 0.048% $ 61.6k | |
| Chief Operating Officer | 3.4yrs | US$903.02k | 0.13% $ 171.2k | |
| Chief Development Officer | 2.8yrs | US$799.36k | 0.026% $ 33.1k | |
| Chief Medical Officer | less than a year | US$94.20k | 0% $ 0 | |
| Chief Technology Officer | 1.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | less than a year | sin datos | sin datos | |
| Senior VP & General Counsel | 3.3yrs | US$1.33m | 0.031% $ 39.9k | |
| Chief People Officer | 5.3yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | sin datos | sin datos | |
| Senior Vice President of Quality | 3.1yrs | sin datos | sin datos | |
| Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations | no data | sin datos | sin datos |
2.8yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ADVM se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.4yrs | US$1.55m | 0.34% $ 433.8k | |
| Independent Director | 5.5yrs | US$111.70k | 0.050% $ 63.6k | |
| Independent Director | 4.6yrs | US$106.70k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Independent Chairman | 7.7yrs | US$163.80k | 0.042% $ 54.3k | |
| Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Independent Director | 3.8yrs | US$99.20k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$106.70k | 0.024% $ 30.8k | |
| Independent Director | 5.5yrs | US$99.20k | 0.062% $ 80.1k | |
| Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Scientific Advisory Board Member | no data | sin datos | sin datos | |
| Director | less than a year | sin datos | sin datos |
4.5yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de ADVM se considera experimentada (4.5 años de antigüedad promedio).